Key facts
- mPharma’s last known valuation is $113.5M (Apr 2020).
- It has raised $89.4M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Microsoft for Startups, Lux Capital, Western Technology Investment, Alchemist Accelerator, Breyer Capital — 35 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 35 names
- ·Watchlist + deal alerts for mPharma
- ·The full record, as it builds
Funding rounds
No funding rounds for mPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About mPharma
Developer of a pharmaceutical data analytics platform designed to make prescription drugs accessible and affordable in emerging markets. The company's platform manages prescription drug inventory for pharmacies and their suppliers and helps them to prescribe and locate the medicines they need and report adverse drug reactions, enabling pharmacies to guarantee the medicines that are needed are always available and affordable.
- Sector
- Healthcare
- HQ
- Accra, Ghana
- Founded
- 2013
- Employees
- 425
- Website
- mpharma.com/
- Ownership
- Privately Held (backing)
mPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in mPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on mPharma in its N-PORT filings yet. We sweep new filings monthly.